VADIM BARAM: Open Payments
NPI 1124007380 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$517,139 in 1,079 payments from 22 companies in 2025. Trend: 2023 $352,097 · 2024 $199,763 · 2025 $517,139
Speaker / faculty: $408,810Travel & lodging: $59,886Food & beverage: $21,635Consulting: $19,613Speaker / faculty: $7,088Education: $108
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 380 | $249,562 |
| Alkermes, Inc. | 147 | $94,449 |
| E.R. Squibb & Sons, L.L.C. | 113 | $69,494 |
| Teva Pharmaceuticals USA, Inc. | 125 | $66,269 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 76 | $18,180 |
| Noven Therapeutics, LLC | 17 | $8,300 |
| ACADIA Pharmaceuticals Inc | 22 | $6,163 |
| Neurocrine BioSciences, Inc. | 61 | $1,226 |
| ABBVIE INC. | 36 | $976 |
| Axsome Therapeutics, Inc. | 32 | $772 |
Products named: FANAPT, COBENFY, LYBALVI, UZEDY, ARISTADA, AUSTEDO XR, CAPLYTA, Xelstrym.
Industry payments across MO — which companies pay providers there.
